tiprankstipranks
Trending News
More News >

Protagenic Therapeutics Secures $3.1M for Drug Development

Story Highlights
Protagenic Therapeutics Secures $3.1M for Drug Development

Don’t Miss TipRanks’ Half-Year Sale

An update from Protagenic Therapeutics ( (PTIX) ) is now available.

On May 21, 2025, Protagenic Therapeutics announced it received $3.1 million from recent warrant exchanges and exercises. This funding will support working-capital needs and advance its drug candidates for stress-related and central-nervous-system disorders, coinciding with its business combination with Phytanix Bio Inc., which expands its drug programs to include stress disorders, epilepsy, and obesity.

Spark’s Take on PTIX Stock

According to Spark, TipRanks’ AI Analyst, PTIX is a Underperform.

Protagenic Therapeutics faces significant financial difficulties, with no revenue and persistent losses. Technical indicators suggest weak market momentum, and the company’s valuation is unattractive due to negative earnings. These factors collectively result in a low overall stock score, reflecting substantial risks and challenges.

To see Spark’s full report on PTIX stock, click here.

More about Protagenic Therapeutics

Protagenic Therapeutics, Inc. is a company focused on pioneering peptide-based therapies for stress-related disorders, operating in the pharmaceutical industry.

Average Trading Volume: 2,123,447

Technical Sentiment Signal: Hold

Current Market Cap: $6.54M

See more insights into PTIX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1